Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$151.43
-2.8%
$145.13
$111.09
$169.37
$9.19B0.62467,387 shs655,858 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$67.94
-3.9%
$67.75
$60.63
$94.85
$12.96B0.331.85 million shs1.29 million shs
Elevance Health, Inc. stock logo
ELV
Elevance Health
$433.02
-0.4%
$406.34
$362.21
$567.26
$98.45B0.861.40 million shs1.28 million shs
Elevance Health, Inc. stock logo
ELV
Elevance Health
$433.02
-0.4%
$406.34
$362.21
$567.26
$98.45B0.861.40 million shs1.28 million shs
Humana Inc. stock logo
HUM
Humana
$264.55
0.0%
$269.37
$213.31
$406.46
$31.93B0.571.76 million shs927,232 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-2.84%-5.97%-3.29%+9.99%-0.36%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-3.89%-5.02%-4.53%+3.36%-22.00%
Elevance Health, Inc. stock logo
ELV
Elevance Health
-0.56%+2.36%+9.05%+17.38%-16.07%
Elevance Health, Inc. stock logo
ELV
Elevance Health
-0.56%+2.36%+9.05%+17.38%-16.07%
Humana Inc. stock logo
HUM
Humana
+0.07%-3.28%-2.35%+4.27%-24.73%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.1021 of 5 stars
4.51.00.00.03.51.70.6
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
4.928 of 5 stars
4.43.00.03.33.42.53.1
Elevance Health, Inc. stock logo
ELV
Elevance Health
4.6418 of 5 stars
3.53.04.20.04.22.52.5
Elevance Health, Inc. stock logo
ELV
Elevance Health
4.6418 of 5 stars
3.53.04.20.04.22.52.5
Humana Inc. stock logo
HUM
Humana
4.0985 of 5 stars
2.15.02.53.93.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.93
Moderate Buy$204.6435.14% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.71
Moderate Buy$94.0038.36% Upside
Elevance Health, Inc. stock logo
ELV
Elevance Health
2.94
Moderate Buy$519.8120.04% Upside
Elevance Health, Inc. stock logo
ELV
Elevance Health
2.94
Moderate Buy$519.8120.04% Upside
Humana Inc. stock logo
HUM
Humana
2.23
Hold$285.687.99% Upside

Current Analyst Ratings Breakdown

Latest ASND, BMRN, ELV, HUM, and ELV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/28/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/18/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.00
3/17/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$450.00
3/17/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$450.00
2/25/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.00
2/24/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$98.00
2/20/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$94.00
2/20/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$81.00 ➝ $82.00
2/20/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$78.00 ➝ $80.00
2/20/2025
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$70.00 ➝ $70.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$363.64M25.27N/AN/A($1.88) per share-80.55
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$2.85B4.54$3.21 per share21.17$29.69 per share2.29
Elevance Health, Inc. stock logo
ELV
Elevance Health
$176.81B0.56$43.43 per share9.97$178.62 per share2.42
Elevance Health, Inc. stock logo
ELV
Elevance Health
$176.81B0.56$43.43 per share9.97$178.62 per share2.42
Humana Inc. stock logo
HUM
Humana
$117.76B0.27$23.27 per share11.37$136.57 per share1.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$7.10N/A630.96N/A-104.54%N/A-39.23%5/1/2025 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$167.65M$2.2030.8815.580.6114.96%9.91%7.65%4/23/2025 (Estimated)
Elevance Health, Inc. stock logo
ELV
Elevance Health
$5.98B$25.6116.9111.091.183.38%18.28%6.72%4/22/2025 (Estimated)
Elevance Health, Inc. stock logo
ELV
Elevance Health
$5.98B$25.6116.9111.091.183.38%18.28%6.72%4/22/2025 (Estimated)
Humana Inc. stock logo
HUM
Humana
$1.21B$9.9526.5920.152.051.02%11.70%3.99%4/23/2025 (Estimated)

Latest ASND, BMRN, ELV, HUM, and ELV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95N/AN/AN/A$741.84 millionN/A
4/23/2025N/A
Humana Inc. stock logo
HUM
Humana
$9.95N/AN/AN/A$32.00 billionN/A
4/22/2025N/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$10.60N/AN/AN/A$46.26 billionN/A
4/22/2025N/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$10.60N/AN/AN/A$46.26 billionN/A
2/19/2025Q4 2024
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.54$0.72+$0.18$0.64$711.05 million$747.31 million
2/12/2025Q4 2024
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A
2/11/2025Q4 2024
Humana Inc. stock logo
HUM
Humana
-$2.26-$2.16+$0.10-$5.76$28.84 billionN/A
1/23/2025Q4 2024
Elevance Health, Inc. stock logo
ELV
Elevance Health
$3.80$3.84+$0.04$1.81$44.63 billionN/A
1/23/2025Q4 2024
Elevance Health, Inc. stock logo
ELV
Elevance Health
$3.80$3.84+$0.04$1.81$44.63 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Elevance Health, Inc. stock logo
ELV
Elevance Health
$6.841.58%+12.99%26.71%14 Years
Elevance Health, Inc. stock logo
ELV
Elevance Health
$6.841.58%+12.99%26.71%14 Years
Humana Inc. stock logo
HUM
Humana
$3.541.34%+8.13%35.58%N/A

Latest ASND, BMRN, ELV, HUM, and ELV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/20/2025
Humana Inc. stock logo
HUM
Humana
quarterly$0.88501.33%3/28/20253/28/20254/25/2025
1/22/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
quarterly$1.711.75%3/10/20253/10/20253/25/2025
1/22/2025
Elevance Health, Inc. stock logo
ELV
Elevance Health
quarterly$1.711.75%3/10/20253/10/20253/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.11
5.33
2.62
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.71
1.45
1.50
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.71
1.45
1.50
Humana Inc. stock logo
HUM
Humana
0.68
1.76
1.76

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Elevance Health, Inc. stock logo
ELV
Elevance Health
89.24%
Elevance Health, Inc. stock logo
ELV
Elevance Health
89.24%
Humana Inc. stock logo
HUM
Humana
92.38%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
1.85%
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.35%
Elevance Health, Inc. stock logo
ELV
Elevance Health
0.35%
Humana Inc. stock logo
HUM
Humana
0.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01760.69 million36.41 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,401190.78 million187.06 millionOptionable
Elevance Health, Inc. stock logo
ELV
Elevance Health
102,300227.35 million231.11 millionOptionable
Elevance Health, Inc. stock logo
ELV
Elevance Health
102,300227.35 million231.11 millionOptionable
Humana Inc. stock logo
HUM
Humana
67,100120.69 million120.03 millionOptionable

Recent News About These Companies

AM Best maintains Humana credit rating
Humana Inc. stock logo
Norges Bank Acquires New Shares in Humana Inc. (NYSE:HUM)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$151.43 -4.43 (-2.84%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$153.10 +1.67 (+1.10%)
As of 04/1/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$67.94 -2.75 (-3.89%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$67.49 -0.45 (-0.66%)
As of 04/1/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Elevance Health stock logo

Elevance Health NYSE:ELV

$433.02 -1.95 (-0.45%)
Closing price 04/1/2025 03:59 PM Eastern
Extended Trading
$432.76 -0.25 (-0.06%)
As of 04/1/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health stock logo

Elevance Health NYSE:ELV

$433.02 -1.95 (-0.45%)
Closing price 04/1/2025 03:59 PM Eastern
Extended Trading
$432.76 -0.25 (-0.06%)
As of 04/1/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Humana stock logo

Humana NYSE:HUM

$264.55 -0.05 (-0.02%)
Closing price 04/1/2025 03:59 PM Eastern
Extended Trading
$264.56 +0.01 (+0.00%)
As of 04/1/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.